RT Journal Article
SR Electronic
T1 Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.19.21255739
DO 10.1101/2021.04.19.21255739
A1 Cohen, Kristen W.
A1 Linderman, Susanne L.
A1 Moodie, Zoe
A1 Czartoski, Julie
A1 Lai, Lilin
A1 Mantus, Grace
A1 Norwood, Carson
A1 Nyhoff, Lindsay E.
A1 Edara, Venkata Viswanadh
A1 Floyd, Katharine
A1 De Rosa, Stephen C.
A1 Ahmed, Hasan
A1 Whaley, Rachael
A1 Patel, Shivan N.
A1 Prigmore, Brittany
A1 Lemos, Maria P.
A1 Davis, Carl W.
A1 Furth, Sarah
A1 O’Keefe, James
A1 Gharpure, Mohini P.
A1 Gunisetty, Sivaram
A1 Stephens, Kathy A.
A1 Antia, Rustom
A1 Zarnitsyna, Veronika I.
A1 Stephens, David S.
A1 Edupuganti, Srilatha
A1 Rouphael, Nadine
A1 Anderson, Evan J.
A1 Mehta, Aneesh K.
A1 Wrammert, Jens
A1 Suthar, Mehul S.
A1 Ahmed, Rafi
A1 Juliana McElrath, M.
YR 2021
UL http://medrxiv.org/content/early/2021/06/18/2021.04.19.21255739.abstract
AB Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we evaluate 254 COVID-19 patients longitudinally up to eight months and find durable broad-based immune responses. SARS-CoV-2 spike binding and neutralizing antibodies exhibit a bi-phasic decay with an extended half-life of >200 days suggesting the generation of longer-lived plasma cells. SARS-CoV-2 infection also boosts antibody titers to SARS-CoV-1 and common betacoronaviruses. In addition, spike-specific IgG+ memory B cells persist, which bodes well for a rapid antibody response upon virus re-exposure or vaccination. Virus-specific CD4+ and CD8+ T cells are polyfunctional and maintained with an estimated half-life of 200 days. Interestingly, CD4+ T cell responses equally target several SARS-CoV-2 proteins, whereas the CD8+ T cell responses preferentially target the nucleoprotein, highlighting the potential importance of including the nucleoprotein in future vaccines. Taken together, these results suggest that broad and effective immunity may persist long-term in recovered COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research reported in this publication was supported in part by COVID supplements from the National Institute of Allergy and Infectious Diseases and the Office of the Director of the National Institutes of Health under award numbers UM1AI068618-14S1 and UM1AI069481-14S1 (MJM); UM1A057266-S1, U19AI057266-17S1, 1U54CA260563, and U19AI090023 (R. Ahmed); ORIP/OD P51OD011132 (MSS); and T32AI074492 (LEN). This work was also supported by grants from the Oliver S. and Jennie R. Donaldson Charitable Trust (R. Ahmed); Paul G. Allen Family Foundation Award #12931 (MJM); Seattle COVID-19 Cohort Study (Fred Hutchinson Cancer Research Center, MJM); the Joel D. Meyers Endowed Chair (MJM); An Emory EVPHA Synergy Fund award (MSS and JW); COVID-Catalyst-I3 Funds from the Woodruff Health Sciences Center (MSS); the Center for Childhood Infections and Vaccines (MSS and JW); Children's Healthcare of Atlanta (MSS and JW), a Woodruff Health Sciences Center 2020 COVID-19 CURE Award (MSS) and the Vital Projects/Proteus funds. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Two longitudinal COVID-19 cohort studies at Fred Hutchinson Cancer Research Center (Seattle, Washington) and Emory University (Atlanta, Georgia) began after receiving institutional review board approvals (IRB 10440, IRB 00001080 and IRB00022371).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is provided in the manuscript.